Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7584 USD | -0.35% | -6.38% | +33.05% |
07:05pm | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
May. 14 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.05% | 29.89M | |
+63.99% | 62.59B | |
-2.01% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.50% | 26.21B | |
-21.93% | 19.09B | |
+3.88% | 13.08B | |
+25.37% | 12.26B | |
+27.38% | 12.05B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- RBC Cuts Price Target on Viracta Therapeutics to $8 From $10, Maintains Outperform, Speculative Risk